Rhumbline Advisers Crispr Therapeutics Ag Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
A detailed history of Rhumbline Advisers transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Rhumbline Advisers holds 123,893 shares of CRSP stock, worth $9.51 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
123,893Holding current value
$9.51 Million% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding CRSP
# of Institutions
533Shares Held
68.7MCall Options Held
3.67MPut Options Held
2.25M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$782 Million4.09% of portfolio
-
Capital International Investors Los Angeles, CA5.59MShares$429 Million0.05% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.68MShares$283 Million0.11% of portfolio
-
State Street Corp Boston, MA3.27MShares$251 Million0.01% of portfolio
-
Ubs Group Ag2.84MShares$218 Million0.02% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $5.99B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....